RESUMEN
Tumor hypoxia may compromise the results of chemotherapy for treating colorectal cancer because it stimulates angiogenesis and the release of tumor growth factors. Hyperbaric oxygen (HBO) supplementation may potentiate the effects of chemotherapy in such cases. This study aimed to assess the effect of HBO therapy combined with chemotherapy on the treatment of colorectal cancer in mice. C57BL6 mice were submitted to the intrarectal instillation of N-methyl-N-nitrosoguanidine (MNNG) and treated with 5-fluorouracil (5FU) and/or HBO therapy. The MNNG group presented the highest dysplastic crypt rate. The 5FU + HBO group presented the highest rate of apoptotic cells per dysplastic crypt. The 5FU group presented the highest expression of hypoxia-inducible factor-1 alpha and CD44. HBO therapy increased the effect of 5FU on the treatment of the experimental colorectal neoplasia in mice.
Asunto(s)
Neoplasias Colorrectales , Fluorouracilo , Oxigenoterapia Hiperbárica , Ratones Endogámicos C57BL , Animales , Fluorouracilo/farmacología , Ratones , Neoplasias Colorrectales/terapia , Neoplasias Colorrectales/patología , Neoplasias Colorrectales/tratamiento farmacológico , Masculino , Antimetabolitos Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Subunidad alfa del Factor 1 Inducible por Hipoxia/metabolismo , Receptores de Hialuranos/metabolismo , Terapia Combinada , Metilnitronitrosoguanidina/farmacologíaRESUMEN
BACKGROUND AND PURPOSE: Fibromyalgia is a complex clinical disorder with an unknown aetiology, characterized by generalized pain and co-morbid symptoms such as anxiety and depression. An imbalance of oxidants and antioxidants is proposed to play a pivotal role in the pathogenesis of fibromyalgia symptoms. However, the precise mechanisms by which oxidative stress contributes to fibromyalgia-induced pain remain unclear. The transient receptor potential ankyrin 1 (TRPA1) channel, known as both a pain sensor and an oxidative stress sensor, has been implicated in various painful conditions. EXPERIMENTAL APPROACH: The feed-forward mechanism that implicates reactive oxygen species (ROS) driven by TRPA1 was investigated in a reserpine-induced fibromyalgia model in C57BL/6J mice employing pharmacological interventions and genetic approaches. KEY RESULTS: Reserpine-treated mice developed pain-like behaviours (mechanical/cold hypersensitivity) and early anxiety-depressive-like disorders, accompanied by increased levels of oxidative stress markers in the sciatic nerve tissues. These effects were not observed upon pharmacological blockade or global genetic deletion of the TRPA1 channel and macrophage depletion. Furthermore, we demonstrated that selective silencing of TRPA1 in Schwann cells reduced reserpine-induced neuroinflammation (NADPH oxidase 1-dependent ROS generation and macrophage increase in the sciatic nerve) and attenuated fibromyalgia-like behaviours. CONCLUSION AND IMPLICATIONS: Activated Schwann cells expressing TRPA1 promote an intracellular pathway culminating in the release of ROS and recruitment of macrophages in the mouse sciatic nerve. These cellular and molecular events sustain mechanical and cold hypersensitivity in the reserpine-evoked fibromyalgia model. Targeting TRPA1 channels on Schwann cells could offer a novel therapeutic approach for managing fibromyalgia-related behaviours.
Asunto(s)
Fibromialgia , Ratones Endogámicos C57BL , Estrés Oxidativo , Especies Reactivas de Oxígeno , Reserpina , Células de Schwann , Canal Catiónico TRPA1 , Animales , Reserpina/farmacología , Fibromialgia/inducido químicamente , Fibromialgia/metabolismo , Canal Catiónico TRPA1/metabolismo , Canal Catiónico TRPA1/antagonistas & inhibidores , Canal Catiónico TRPA1/genética , Estrés Oxidativo/efectos de los fármacos , Células de Schwann/metabolismo , Células de Schwann/efectos de los fármacos , Masculino , Ratones , Especies Reactivas de Oxígeno/metabolismo , Dolor/metabolismo , Dolor/inducido químicamente , Nervio Ciático/metabolismo , Modelos Animales de Enfermedad , Ratones Noqueados , Canales de Potencial de Receptor Transitorio/metabolismo , Canales de Potencial de Receptor Transitorio/antagonistas & inhibidores , Canales de Potencial de Receptor Transitorio/genéticaRESUMEN
Selenium-containing compounds have emerged as promising treatment for redox-based and inflammatory diseases. This study aimed to investigate the in vitro and in vivo anti-inflammatory activity of a novel diselenide named as dibenzyl[diselanediyIbis(propane-3-1diyl)] dicarbamate (DD). DD reacted with HOCl (k = 9.2 x 107 M-1s-1), like glutathione (k = 1.2 x 108 M-1s-1), yielding seleninic and selenonic acid derivatives, and it also decreased HOCl formation by activated human neutrophils (IC50=4.6 µM) and purified myeloperoxidase (MPO) (IC50=3.8 µM). However, tyrosine, MPO-I and MPO-II substrates, did not restore HOCl formation in presence of DD. DD inhibited the oxidative burst in dHL-60 cells with no toxicity up to 25 µM for 48h. Next, an intraperitoneal administration of 25, 50, and 75 mg/kg DD decreased total leukocyte, neutrophil chemotaxis, and inflammation markers (MPO activity, lipid peroxidation, albumin exudation, nitrite, TNF-α, IL-1ß, CXCL1/KC, and CXCL2/MIP-2) on a murine model of carrageenan-induced peritonitis. Likewise, 50 mg/kg DD (i.p.) decreased carrageenan-induced paw edema over 5h. Histological and immunohistochemistry analyses of the paw tissue showed decreased neutrophil count, edema area, and MPO, carbonylated, and nitrated protein staining. Furthermore, DD treatment decreased the fMLP-induced chemotaxis of human neutrophils (IC50=3.7 µM) in vitro with no toxicity. Lastly, DD presented no toxicity in a single-dose model using mice (50 mg/kg, i.p.) over 15 days and in Artemia salina bioassay (50 to 2000 µM), corroborating findings from in silico toxicological study. Altogether, these results demonstrate that DD attenuates carrageenan-induced inflammation mainly by reducing neutrophil migration and the resulting damage from MPO-mediated oxidative burst.
Asunto(s)
Carragenina , Inflamación , Infiltración Neutrófila , Animales , Ratones , Humanos , Inflamación/tratamiento farmacológico , Inflamación/inducido químicamente , Infiltración Neutrófila/efectos de los fármacos , Masculino , Neutrófilos/efectos de los fármacos , Neutrófilos/metabolismo , Edema/tratamiento farmacológico , Edema/inducido químicamente , Peroxidasa/metabolismo , Antiinflamatorios/farmacología , Antiinflamatorios/uso terapéutico , Compuestos de Organoselenio/farmacología , Compuestos de Organoselenio/uso terapéutico , Ácido HipoclorosoRESUMEN
Background: Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1β exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1β in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. Methods: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1β using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. Results: Intravenous administration of recombinant Phα1β toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. Conclusion: Our data suggest that intravenous administration of recombinant Phα1β may be feasible for drug-induced analgesia, without causing any severe side effects.
Asunto(s)
Masculino , Animales , Ratas , Analgésicos , Neuropatía Ciática/terapia , Paclitaxel , Toxinas Biológicas/administración & dosificación , Toxinas Biológicas/efectos adversos , Venenos de Araña/química , Administración Intravenosa , Ratones Endogámicos BALB C , Ratas WistarRESUMEN
Intrathecal injection of voltage-sensitive calcium channel blocker peptide toxins exerts analgesic effect in several animal models of pain. Upon intrathecal administration, recombinant Phα1ß exerts the same analgesic effects as the those of the native toxin. However, from a clinical perspective, the intrathecal administration limits the use of anesthetic drugs in patients. Therefore, this study aimed to investigate the possible antinociceptive effect of intravenous recombinant Phα1ß in rat models of neuropathic pain, as well as its side effects on motor, cardiac (heart rate and blood pressure), and biochemical parameters. Methods: Male Wistar rats and male Balb-C mice were used in this study. Giotto Biotech® synthesized the recombinant version of Phα1ß using Escherichia coli expression. In rats, neuropathic pain was induced by chronic constriction of the sciatic nerve and paclitaxel-induced acute and chronic pain. Mechanical sensitivity was evaluated using von Frey filaments. A radiotelemeter transmitter (TA11PA-C10; Data Sciences, St. Paul, MN, USA) was placed on the left carotid of mice for investigation of cardiovascular side effects. Locomotor activity data were evaluated using the open-field paradigm, and serum CKMB, TGO, TGP, LDH, lactate, creatinine, and urea levels were examined. Results: Intravenous administration of recombinant Phα1ß toxin induced analgesia for up to 4 h, with ED50 of 0.02 (0.01-0.03) mg/kg, and reached the maximal effect (Emax = 100% antinociception) at a dose of 0.2 mg/kg. No significant changes were observed in any of the evaluated motor, cardiac or biochemical parameters. Conclusion: Our data suggest that intravenous administration of recombinant Phα1ß may be feasible for drug-induced analgesia, without causing any severe side effects.(AU)
Asunto(s)
Animales , Ratones , Ratas , Péptidos , Inyecciones Espinales , Proteínas Recombinantes , Analgesia , Fenómenos Bioquímicos , Preparaciones FarmacéuticasRESUMEN
OBJECTIVE: to verify whether the Paw Edema Model can be used in investigations about the effects of Therapeutic Touch on inflammation by measuring the variables pain, edema and neutrophil migration. METHOD: this is a pilot and experimental study, involving ten male mice of the same genetic strain and divided into experimental and control group, submitted to the chemical induction of local inflammation in the right back paw. The experimental group received a daily administration of Therapeutic Touch for 15 minutes during three days. RESULTS: the data showed statistically significant differences in the nociceptive threshold and in the paw circumference of the animals from the experimental group on the second day of the experiment. CONCLUSION: the experiment model involving animals can contribute to study the effects of Therapeutic Touch on inflammation, and adjustments are suggested in the treatment duration, number of sessions and experiment duration.
OBJETIVO: verificar se o modelo de edema de pata pode ser utilizado nas investigações acerca dos efeitos do toque terapêutico sobre a inflamação, mensurando-se as variáveis dor, edema e migração de neutrófilos. MÉTODO: trata-se de estudo piloto, experimental, com 10 camundongos machos da mesma linhagem genética, divididos em grupo experimental e controle, submetidos à indução química de inflamação local na pata direita traseira. O grupo experimental recebeu uma aplicação diária de toque terapêutico com duração de quinze minutos, por três dias. RESULTADOS: os dados evidenciaram diferenças estatisticamente significativas no limiar nociceptivo e na circunferência das patas dos animais do grupo experimental, no segundo dia do experimento. CONCLUSÃO: o modelo de experimento com animal pode contribuir para o estudo dos efeitos do toque terapêutico sobre a inflamação. Sugere-se ajuste no tempo de exposição, número de sessões e tempo de duração do experimento.
OBJETIVO: verificar si el Modelo de Edema de Pata puede ser utilizado en las investigaciones acerca de los efectos del Toque Terapéutico sobre la inflamación, mensurándose las variables dolor, edema y migración de neutrófilos. MÉTODO: se trata de un estudio piloto, experimental, con 10 ratones machos del mismo linaje genético, divididos en grupo experimental y control, sometidos a inducción química de inflamación local en la pata derecha trasera. O grupo experimental recibió una aplicación diaria de Toque Terapéutico con duración de quince minutos, por tres días. RESULTADOS: Los datos evidenciaron diferencias estadísticamente significativas en el umbral de nocicepción y circunferencia de las patas de los animales del grupo experimental durante el segundo día del experimento. CONCLUSIÓN: El modelo de experimento con animal puede contribuir al estudio de los efectos del Toque Terapéutico sobre la inflamación: se sugiere ajuste en el tiempo de exposición, número de sesiones y duración del experimento.